Michael S. Cookson, MD, MMHC, FACS, is professor and chairman of the Department of Urology at the University of Oklahoma Health Sciences Center, and he holds the Donald D. Albers, M.D. Endowed Chair in Urology. 

Dr Cookson is nationally recognized for his outstanding contributions to urologic oncology. An accomplished researcher and lecturer, he is the author of 253 peer-reviewed journal publications and 34 chapters of various textbooks. He has also served as editor of 2 books in urology and urologic surgery and is the co–editor in chief of the Urology Times. He is the 2019 to 2021 president of the Society of Urologic Oncology and the 2020 to 2021 president of the South Central Section of the American Urological Association (AUA).

He has devoted a significant portion of his academic career to the treatment of patients with urologic cancers, with a strong emphasis on clinical guidelines, education, and evidenced-based medicine. He is a cofounder of the Oncology Knowledge Assessment Test (OKAT), a Society of Urologic Oncology–mandated oncology examination that is the standard for benchmarking for members and oncology fellows in training. Dr Cookson served as chair of that OKAT committee for 5 years. In 2018, he received an AUA Presidential Citation for outstanding service for his role in the development of the OKAT and as chair of the Castration-Resistant Prostate Cancer AUA guideline from the AUA 2018 Annual Meeting. 

Robert Dreicer, MD, MS, MACP, FASCO, is the associate director for clinical research and the deputy director of the University of Virginia Comprehensive Cancer Center. He also serves as section mead of medical oncology and co-director of the Paul Mellon Urologic Cancer Institute. He is a professor of medicine and urology at the University of Virginia School of Medicine in Charlottesville. He previously served as chair of the Department of Solid Tumor Oncology at the Cleveland Clinic and deputy associate director for clinical research at the Case Comprehensive Cancer Center. 

Dr Dreicer received his BS degree at Colorado State University and his MS degree at The University of Texas Graduate School of Biomedical Sciences in Houston. He received his MD from The University of Texas Medical School at Houston. He completed an internal medicine residency at Indiana University in Indianapolis, followed by a medical oncology fellowship at the University of Wisconsin Carbone Cancer Center in Madison.

He is board certified in internal medicine and medical oncology. His areas of specialization are in the management of genitourinary malignancies and the design and conduct of clinical trials in urologic oncology. Dr Dreicer has published extensively in genitourinary oncology, and he has served as principal investigator for a large number of studies in genitourinary neoplasms. He served as co-chair of National Cancer Institute Genitourinary Cancers Steering Committee from 2012 to 2018 and is an editorial board member for The New England Journal of Medicine’s Journal Watch Oncology and Hematology. He also currently serves on the American Board of Internal Medicine’s Medical Oncology Longitudinal Assessment Approval Committee. In October 2016, he was awarded Mastership in the American College of Physicians.

William K. Oh, MD, is chief medical science officer at Sema4, a patient-centered health intelligence company focused on precision medicine. He is also clinical professor of medicine in the Division of Hematology and Medical Oncology at the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai. 

Dr Oh received his MD from New York University School of Medicine. He completed his internship and residency in internal medicine at Brigham and Women’s Hospital in Boston and completed his medical oncology fellowship at the Dana-Farber Cancer Institute. He was at the Dana-Farber Cancer Institute and Harvard Medical School for 14 years, where he served as clinical director of the Lank Center for Genitourinary Oncology and was founding chair of the Data and Safety Monitoring Committee at the Dana-Farber/Harvard Cancer Center. Most recently, Dr Oh was chief of the Division of Hematology and Medical Oncology at the Icahn School of Medicine at Mount Sinai for 11 years. He also served as deputy director of the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai, which he helped to achieve National Cancer Institute designation in 2015 and renewed in 2020.

Dr Oh is an expert in the management of genitourinary (GU) malignancies, including prostate, renal, bladder, and testicular cancers. A leading investigator in the use of systemic treatments for prostate cancer, Dr Oh has served as the principal investigator for multiple clinical trials in GU cancers. In addition, he has developed large clinical databases and specimen repositories for GU cancers at both Harvard and Mount Sinai. He has authored more than 300 original articles, reviews, and book chapters on topics related to prostate, renal, bladder, and testicular cancers. He has also edited 3 books on prostate cancer. 

Dr Oh has served in key invited roles for the American Society of Clinical Oncology, the American Cancer Society, and the American Urological Association, including the Guidelines Committee for Castration-Resistant Prostate Cancer. He was inducted into the prestigious American Society for Clinical Investigation and has been repeatedly selected as a Top Doctor in New York Magazine, Castle Connolly, Best Doctors, and Super Doctors through 2021.